Cardiovascular Stem Cell Therapy · 2019-03-26 · Cardiovascular Stem Cell Therapy Results A total...
Transcript of Cardiovascular Stem Cell Therapy · 2019-03-26 · Cardiovascular Stem Cell Therapy Results A total...
Cardiovascular Stem Cell TherapyResults
A total number of 21 patients with heart complications were put under observation after the ischemic heart disease therapy.
A whopping 88% of the patients showed clinical improvements.
Few of the various improvements reported were - less shortness of breath, reduction in medication, less weakness, less tiredness and less edema. In one case the pacemaker could be turned down.
The average percentage of development of the Left Ventricular Ejection Fraction (LVEF) which is a measure of the heart function was 24.2%.
Percentage improved heart disease patients
Improvement No Change
100%
80%
60%
40%
20%
0%
Improvements of LVEF
LVEF - values before and after treatment
1 2 3 4 5 6 7 8 9 10 11 12 13
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Mean LVEF increase
100%90%80%70%60%50%40%30%20%10%0%
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Delta%
Delta% After
LEVF befor and after ASCT01 treatment
Before After
45%
40%
35%
30%
25%
20%
15%
Results From Adipose Derived StemCells
Methods :-• 60 cc’s adipose tissue removed via local tumescent
anesthesia • Fat washed to remove red blood cells • Enzymatic digestion with Adipolase • Centrifugation to separate stromal vascular fraction • Washing and filtration • Cell delivered to patient
Criteria :- • Intramyocardial delivery via MyoCath catheter • Number and frequency Of adverse events • Changes in left ventricular ejection fraction (LVEF) • Exercise capability • Quality Of life
Results :-• 615 patients treated • Average improvement Of Il points in LVEF • Average increase of 128 meters in 6 minute walk exercise capacity test
Bioheart MyoCathTM
Trial ICongestive Heart Failure
Baseline 3 Month
100%90%80%70%60%50%40%30%20%10%
p = 0.04, N = 5
%LV
EF
Baseline 3 Month
600
550
500
450
400
p = 0.04, N = 5
Dis
tanc
e (M
eter
s)
Left Ventricular Ejection Fraction Exercise Capacity - Six Minute Walk Distance
Conclusions :-• Adipose tissue is readily available and a plentiful source Of Stem cells • Preliminary data for COPO CHF and wound healing demonstrates strong safety profile in patients. • ADSCs can be utilized in degenerative diseases to promote reduction of inflammation and healing.
Trial IIANGEL TRIAL
Product Specifications :-• ADSC from 60 cc’s Of fat processed at point Of Care in 35 minutes • Delivered intra-myocardiany Via Catheter in 4 ml Saline
Co - Primary Efficacy Endpoints :- • Exercise capacity (6 min walk test) • Quality of life (MLFHF)
Secondary Efficacy Endpoints :-• Ejection Fraction
Left Ventricular Election Fraction
Ejection Fraction
Per
cenr
age
50%45%40%35%30%25%20%15%10%5%0%
Baseline
3 Month
6 Month
100 101 102 103 104
Baseline 40% 20% 40% 39% 39%
3 Month 40% 30% 42% 42% 33%
6 Month 45% 35% 45% 45% 44%
Base line (N = 5)
3 Month (N = 5)
6 Month (N = 5)
P = 0.01
P = 0.17
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
Minnesota Living with Heart Failure
MLWHF Scores
Per
cenr
age
100%90%80%70%60%50%40%30%20%10%0%
Baseline
3 Month
6 Month
pt 100 pt 101 pt 102 pt 103 pt 104
Baseline 61% 55% 13% 62% 25%
3 Month 13% 47% 4% 58% 32%
6 Month 19% 34% 18% 47% 42%
Exercise Capacity
Distance 8MW
Per
cenr
age
600550500450400350300250200150100500
Baseline
3 Month
6 Month
100 101 102 103 104
Baseline 158 385 485 180 260
3 Month 295 450 550 200 240
6 Month 305 465 450 290 270
Base line (N = 5)
3 Month (N = 5)
6 Month (N = 5)
P = 0.01
P = 0.17
600550500450400350300250200150100500